SCHEMBL23705374

SCHEMBL23705374

CCSc1cc(C(=O)OC)ccc1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.53
MAPT P10636 7/20 0.53
KDM4E B2RXH2 6/20 0.53
HSD17B10 Q99714 4/20 0.53
HPGD P15428 4/20 0.53
LMNA P02545 3/20 0.53
ALOX15 P16050 2/20 0.53
MEN1 O00255 1/20 0.53
TP53 P04637 1/20 0.53
ALOX12 P18054 1/20 0.53
HTT P42858 1/20 0.53
KMT2A Q03164 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
L3MBTL1 Q9Y468 3/20 0.46
CA12 O43570 2/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA7 P43166 2/20 0.46
CA9 Q16790 2/20 0.46
CA14 Q9ULX7 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31401447 0.84 ALDH1A1 (0.54) ALDH1A1MAPTKDM4EHSD17B10HPGD
SCHEMBL19582008 0.82 NOTUM (0.50) ALDH1A1MAPTKDM4EHSD17B10HPGD
SCHEMBL21374189 0.81 ALDH1A1 (0.57) ALDH1A1MAPTKDM4EHSD17B10HPGD
SCHEMBL23715374 0.80 MAPT (0.49) ALDH1A1MAPTKDM4EHSD17B10HPGD
SCHEMBL23704834 0.80 KDM4E (0.49) ALDH1A1MAPTKDM4EHSD17B10HPGD
SCHEMBL23715041 0.77 ALDH1A1 (0.53) ALDH1A1MAPTKDM4EHSD17B10HPGD
SCHEMBL10309779 0.76 ALDH1A1 (0.54) ALDH1A1MAPTKDM4EHSD17B10HPGD
SCHEMBL31401300 0.76 HSD17B10 (0.51) ALDH1A1MAPTKDM4EHSD17B10HPGD
SCHEMBL13495880 0.75 ALDH1A1 (0.50) ALDH1A1MAPTKDM4EHSD17B10HPGD
SCHEMBL30029511 0.75 MAPT (0.63) ALDH1A1MAPTKDM4EHSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
CN-115484948-A Compound and use thereof 福宏治疗公司 2022-12-16 CN disclosed
EP-4096657-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 EP disclosed
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149414-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB ALDH1A1 2571/4885MAPT 2074/4885KDM4E 1848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.